KPRX (Kiora Pharmaceuticals) Cyclically Adjusted Book per Share: $653.77 (As of Mar. 2026)


KPRX Kiora Pharmaceuticals Inc KPRX
34 GF Score
Price $2.54
! 3 Warning Signs
View Full Analysis

What is Kiora Pharmaceuticals Cyclically Adjusted Book per Share?

Kiora Pharmaceuticals KPRX -0.78% 34 Cyclically Adjusted Book per Share is $653.77 as of Mar. 2026. GuruFocus rates KPRX with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Kiora Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was $3.490. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $653.77 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Kiora Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -48.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-06-29), Kiora Pharmaceuticals's current stock price is $2.54. Kiora Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $653.77. Kiora Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 0.00.


Kiora Pharmaceuticals  (NAS:KPRX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Kiora Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.54/653.77
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Kiora Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Kiora Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Kiora Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiora Pharmaceuticals Cyclically Adjusted Book per Share Chart

Kiora Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -6,483.53 -4,720.60 1,326.91 754.90

Kiora Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,272.48 1,252.75 965.50 754.90 653.77

KPRX vs PHIO, PBM, OSRH: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Kiora Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiora Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Kiora Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


KPRX
34GF Score
Kiora Pharmaceuticals Inc KPRX
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kiora Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kiora Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.49/330.2130*330.2130
=3.490

Current CPI (Mar. 2026) = 330.2130.

Kiora Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 3,234.000 241.018 4,430.826
201609 1,622.500 241.428 2,219.173
201612 -164.500 241.432 -224.991
201703 -573.000 243.801 -776.092
201706 1,523.000 244.955 2,053.089
201709 226.333 246.819 302.805
201712 -642.333 246.524 -860.390
201803 1,759.333 249.554 2,327.972
201806 1,693.500 251.989 2,219.207
201809 1,387.500 252.439 1,814.975
201812 1,117.000 251.233 1,468.151
201903 1,254.875 254.202 1,630.105
201906 1,059.000 256.143 1,365.236
201909 651.500 256.759 837.882
201912 602.000 256.974 773.573
202003 716.769 258.115 916.981
202006 599.846 257.797 768.345
202009 458.538 260.280 581.740
202012 648.667 260.474 822.340
202103 634.250 264.877 790.698
202106 522.700 271.696 635.277
202109 495.657 274.310 596.669
202112 416.543 278.802 493.353
202203 321.657 287.504 369.439
202206 243.389 296.311 271.236
202209 87.675 296.808 97.543
202212 57.040 296.797 63.462
202303 47.681 301.836 52.164
202306 17.763 305.109 19.225
202309 9.489 307.789 10.180
202312 7.138 306.746 7.684
202403 11.966 312.332 12.651
202406 11.142 314.175 11.711
202409 10.007 315.301 10.480
202412 8.584 315.605 8.981
202503 7.897 319.799 8.154
202506 6.445 322.561 6.598
202509 6.528 324.800 6.637
202512 4.287 324.054 4.368
202603 3.490 330.213 3.490

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $653.77 mean?
Kiora Pharmaceuticals (KPRX) has a Cyclically Adjusted Book per Share of $653.77 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Kiora Pharmaceuticals and its competitors.
Is Kiora Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Kiora Pharmaceuticals' current Cyclically Adjusted Book per Share is $653.77. Overall, Kiora Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Kiora Pharmaceuticals' Cyclically Adjusted Book per Share compare to PHIO and PBM?
Kiora Pharmaceuticals' Cyclically Adjusted Book per Share of $653.77 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Kiora Pharmaceuticals and its competitors. Kiora Pharmaceuticals's current Cyclically Adjusted Book per Share is $653.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiora Pharmaceuticals stock overvalued right now?
Kiora Pharmaceuticals (KPRX) has a current Cyclically Adjusted Book per Share of $653.77. The current Cyclically Adjusted Book per Share is $653.77. Kiora Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Kiora Pharmaceuticals (KPRX), the current Cyclically Adjusted Book per Share is $653.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kiora Pharmaceuticals Business Description

Address 169 Saxony Road, Suite 212, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
34GF Score

Get the complete analysis for KPRX

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.54
Price